Presynaptic glutamate release inhibitors for decreasing nmda antagonist side effects in anesthesia
AssigneeThe Cleveland Clinic Foundation
InventorAmit Anand
Life of this patent
Estimating the term…
Abstract
A method of anesthetizing a subject that includes administering a therapeutically effective amount of an NMDA antagonist to the subject is described. The method also includes administering an effective amount of a presynaptic glutamate release inhibitor to the subject to decrease the neurotoxic and/or psychomimetic side effects of the NMDA antagonist. Pharmaceutical compositions including an NMDA antagonist and a presynaptic glutamate release inhibitor are also described.
Claims17
A method of anesthetizing a subject, comprising administering a therapeutically effective amount of an NMDA antagonist to the subject, the method further comprising administering an effective amount of a presynaptic glutamate release inhibitor to the subject to decrease the neurotoxic and/or psychomimetic side effects of the NMDA antagonist.
A pharmaceutical composition comprising a mixture of an NMDA antagonist and a presynaptic glutamate release inhibitor together with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.